Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BL1332 eye drops
BL1332 eye · 1 trial · 1 indication
NPRS scale 0 to 10, with higher score reflecting worse pain
| Arm | Type | Description |
|---|---|---|
| BL1332 eye drops | ACTIVE_COMPARATOR | - |
| BL1332 Placebo eye drops | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BL1332 eye drops | DRUG | Taken 1 time |
| BL1332 Placebo eye drops | DRUG | Taken 1 time |
Inclusion Criteria: * Male or female ≥ 18 to ≤ 65 years of age. * In good health, as assessed at Screening by the Investigator from past medical history, physical examination (abbreviated), and laboratory tests. * Does not wear contact lenses, or is willing to refrain from wearing contact lenses fo...
BL1332 eye is an investigational small molecule being studied as an eye drop formulation for reducing capsaicin-induced ocular pain in healthy trial participants. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
The specific molecular target of BL1332 eye has not been disclosed. The drug is being evaluated for its effect on ocular pain induced by capsaicin in a clinical trial setting.
BL1332 eye is being developed by Bausch Health Companies Inc., a company traded on the stock exchange under the ticker symbol BHC.
BL1332 eye is currently in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 1 trial is actively recruiting participants.
BL1332 eye is being studied in a Phase 1 clinical trial with the identifier NCT07717918, titled 'A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants.' This randomized, double-blind, placebo-controlled trial is recruiting 28 healthy participants in the United States.
Yes, BL1332 eye is also known as BL1332 eye drops. Both names refer to the same investigational drug product being developed by Bausch Health Companies Inc.